Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C6H14N4O2 |
Molecular Weight | 174.201 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=ODKSFYDXXFIFQN-BYPYZUCNSA-N
InChI=1S/C6H14N4O2/c7-4(5(11)12)2-1-3-10-6(8)9/h4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t4-/m0/s1
Molecular Formula | C6H14N4O2 |
Molecular Weight | 174.201 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
L-arginine is a nonessential amino acid that may play an important role in the treatment of cardiovascular disease due to its antiatherogenic, anti-ischemic, antiplatelet, and antithrombotic properties. It has been promoted as a growth stimulant and as a treatment for erectile dysfunction in men. L-arginine is a nonessential amino acid that may play an important role in the treatment of heart disease due to its block arterial plaque buildup, blood clots, platelet clumping, and to increase blood flow through the coronary artery. L-arginine is commonly sold as a health supplement claiming to improve vascular health and treat erectile dysfunction in men. L-arginine, which is promoted as a human growth stimulant, has also been used in bodybuilding. In the 1800s, it was first isolated from animal horn.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q5T6X5 Gene ID: 222545.0 Gene Symbol: GPRC6A Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628 |
44.1 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Diagnostic | R-GENE 10 Approved UseR-Gene 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature.
If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene 10 is approximately 32%, and the rate of false negatives is approximately 27%. Launch Date1973 |
|||
Preventing | Unknown Approved UseUnknown |
|||
Preventing | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
310 μM |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
6219 μM |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
882 μM |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
24788 M × min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
265435 M × min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
38223 M × min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
77.5 min |
6 g single, oral dose: 6 g route of administration: Oral experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
41.6 min |
30 g single, intravenous dose: 30 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
|
59.6 min |
6 g single, intravenous dose: 6 g route of administration: Intravenous experiment type: SINGLE co-administered: |
ARGININE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
100% EXPERIMENT https://www.jci.org/articles/view/103568 |
ARGININE plasma | Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Disc. AE: Cardiopulmonary arrest, Metabolic acidosis... AEs leading to discontinuation/dose reduction: Cardiopulmonary arrest Sources: Page: p.621Metabolic acidosis (acute) Hyponatremia (severe) |
200 mg/kg 3 times / day multiple, oral Highest studied dose Dose: 200 mg/kg, 3 times / day Route: oral Route: multiple Dose: 200 mg/kg, 3 times / day Sources: Page: p.63 |
unhealthy, 24 n = 11 Health Status: unhealthy Condition: Cystic fibrosis Age Group: 24 Sex: M+F Population Size: 11 Sources: Page: p.63 |
|
15 g 2 times / day multiple, oral Studied dose Dose: 15 g, 2 times / day Route: oral Route: multiple Dose: 15 g, 2 times / day Sources: Page: p.1 |
healthy, 34 ± 2.6 n = 12 Health Status: healthy Condition: Dietary supplementation Age Group: 34 ± 2.6 Sex: M+F Population Size: 12 Sources: Page: p.1 |
|
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
DLT: Gastrointestinal discomfort... Dose limiting toxicities: Gastrointestinal discomfort (20%) Sources: Page: p.200 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Cardiopulmonary arrest | Disc. AE | 3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Metabolic acidosis | acute Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Hyponatremia | severe Disc. AE |
3.9 g/kg single, intravenous Accidental dose Dose: 3.9 g/kg Route: intravenous Route: single Dose: 3.9 g/kg Sources: Page: p.621 |
unhealthy, 1.75 n = 1 Health Status: unhealthy Condition: Short stature Age Group: 1.75 Sex: F Population Size: 1 Sources: Page: p.621 |
Gastrointestinal discomfort | 20% DLT |
7 g 3 times / day multiple, oral Studied dose Dose: 7 g, 3 times / day Route: oral Route: multiple Dose: 7 g, 3 times / day Sources: Page: p.200 |
unhealthy, 43± 16 n = 10 Health Status: unhealthy Condition: Hypercholesterolaemia Age Group: 43± 16 Sex: M+F Population Size: 10 Sources: Page: p.200 |
PubMed
Title | Date | PubMed |
---|---|---|
Postabsorptive plasma citrulline concentration is a marker of absorptive enterocyte mass and intestinal failure in humans. | 2000 Dec |
|
A rare case of complete human erythrocyte AMP deaminase deficiency due to two novel missense mutations in AMPD3. | 2001 |
|
The dialytic failure of the peritoneal membrane. | 2001 |
|
Hemodialysis techniques and advanced glycation end products. | 2001 |
|
AGE in micro- and macroangiopathy. | 2001 |
|
Protein traffic in bacteria: multiple routes from the ribosome to and across the membrane. | 2001 |
|
Purification and characterization of calobin II, a second type of thrombin-like enzyme from Agkistrodon caliginosus (Korean viper). | 2001 Apr |
|
Fructose-6-phosphate aldolase is a novel class I aldolase from Escherichia coli and is related to a novel group of bacterial transaldolases. | 2001 Apr 6 |
|
A positively charged cluster formed in the heme-distal pocket of cytochrome P450nor is essential for interaction with NADH. | 2001 Feb 16 |
|
Characterization of homo- and heterodimerization of cardiac Csx/Nkx2.5 homeoprotein. | 2001 Feb 16 |
|
Increased affinity of c-Myb for CREB-binding protein (CBP) after CBP-induced acetylation. | 2001 Feb 2 |
|
Ligand-independent dimerization and activation of the oncogenic Xmrk receptor by two mutations in the extracellular domain. | 2001 Feb 2 |
|
DNA recognition by the methyl-CpG binding domain of MeCP2. | 2001 Feb 2 |
|
Human glutathione transferase T2-2 discloses some evolutionary strategies for optimization of substrate binding to the active site of glutathione transferases. | 2001 Feb 23 |
|
Fibroblast growth factor-2 stimulates endothelial nitric oxide synthase expression and inhibits apoptosis by a nitric oxide-dependent pathway in Nb2 lymphoma cells. | 2001 Jan |
|
Effect of AVT antisense oligodeoxynucleotides on AVT release induced by hypertonic stimulation in chicks. | 2001 Jan |
|
Agmatine enhances the NADPH oxidase activity of neuronal NO synthase and leads to oxidative inactivation of the enzyme. | 2001 Jan |
|
[Ca(2+)](i) signaling in renal arterial smooth muscle cells of pregnant rat is enhanced during inhibition of NOS. | 2001 Jan |
|
An extended hydrophobic interactive surface of Yersinia pestis Caf1M chaperone is essential for subunit binding and F1 capsule assembly. | 2001 Jan |
|
Increased colocalization of corticotropin-releasing factor and arginine vasopressin in paraventricular neurones of the hypothalamus in lactating rats: evidence from immunotargeted lesions and immunohistochemistry. | 2001 Jan |
|
Altered endothelium-dependent relaxations in lambs with high pulmonary blood flow and pulmonary hypertension. | 2001 Jan |
|
Altered TNF-alpha, glucose, insulin, and amino acids in islets of Langerhans cultured in a microgravity model system. | 2001 Jan |
|
Tec kinase signaling in T cells is regulated by phosphatidylinositol 3-kinase and the Tec pleckstrin homology domain. | 2001 Jan 1 |
|
Substitution of Asp114 or Arg116 in the fingers domain of moloney murine leukemia virus reverse transcriptase affects interactions with the template-primer resulting in decreased processivity. | 2001 Jan 12 |
|
Amino acid residues in ribonuclease MC1 from bitter gourd seeds which are essential for uridine specificity. | 2001 Jan 16 |
|
Strain is more important than electrostatic interaction in controlling the pKa of the catalytic group in aspartate aminotransferase. | 2001 Jan 16 |
|
Site-specific single amino acid changes to Lys or Arg in the central region of the movement protein of a hybrid bromovirus are required for adaptation to a nonhost. | 2001 Jan 5 |
|
Pharmacological profile of T-1032, a novel specific phosphodiesterase type 5 inhibitor, in isolated rat aorta and rabbit corpus cavernosum. | 2001 Jan 5 |
|
Crystal structure and novel recognition motif of rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis. | 2001 Jan 5 |
|
L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. | 2001 Jan 5 |
|
C60-Fullerene monomalonate adducts selectively inactivate neuronal nitric oxide synthase by uncoupling the formation of reactive oxygen intermediates from nitric oxide production. | 2001 Jan 9 |
|
Translocation of jellyfish green fluorescent protein via the Tat system of Escherichia coli and change of its periplasmic localization in response to osmotic up-shock. | 2001 Mar 16 |
|
Scanning mutagenesis reveals roles for helix n of the bacteriophage T7 RNA polymerase thumb subdomain in transcription complex stability, pausing, and termination. | 2001 Mar 30 |
|
Identification of the collagen-binding site of the von Willebrand factor A3-domain. | 2001 Mar 30 |
|
The modulation of oxygen radical production by nitric oxide in mitochondria. | 2001 Mar 9 |
|
The fission yeast TOR homolog, tor1+, is required for the response to starvation and other stresses via a conserved serine. | 2001 Mar 9 |
|
Rare somatic p53 mutation identified in breast cancer: a case report. | 2001 Mar-Apr |
|
The role of nitric oxide on the relaxations of rabbit corpus cavernosum induced by Androctonus australis and Buthotus judaicus scorpion venoms. | 2001 May |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/npc/l-arginine.html
Curator's Comment: I.V route is possible: The recommended adult dose is 30 g arginine hydrochloride (300 mL of R-Gene 10) administered by intravenous infusion over 30 minutes. The total dose should not exceed 30 g arginine hydrochloride.
https://www.drugs.com/dosage/r-gene-10.html
L-arginine has been studied at oral doses of 6 to 30 g/day for a variety of conditions. Many formulations have been used.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15576628
A strong inward current in X. laevis oocytes expressing 5.24 (C terminus of the homologous goldfish 5.24 receptor) when L-Arg (L-arginine) was applied at 10 uM. When testing chimera h6A/5.24 (h6A/5.24, containing the ligand binding amino-terminal domain (ATD) of hGPRC6A with the signal transducing transmembrane and C terminus of the homologous goldfish 5.24 receptor) in this system, the responses were obtained with L-Arg at 100 uM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:02:28 GMT 2023
by
admin
on
Fri Dec 15 15:02:28 GMT 2023
|
Record UNII |
94ZLA3W45F
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
54092-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
27974-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
26985-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
55911-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
27296-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
32226-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1895-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
DSLD |
2368 (Number of products:1422)
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
32225-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
15136-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47566-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
WHO-ATC |
B05XB01
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
16401-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
22656-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
DSLD |
116 (Number of products:647)
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
FDA ORPHAN DRUG |
785420
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
30062-4
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
43927-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
53398-4
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47563-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47568-1
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47565-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
25861-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47564-0
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
25322-9
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
13387-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
13708-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
53200-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
22697-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
25860-8
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1891-1
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
JECFA EVALUATION |
L-ARGININE
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1892-9
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
20637-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
41168-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
56672-9
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
75214-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1893-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
1894-5
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
44299-6
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47562-4
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
22727-2
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
15140-7
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
||
|
LOINC |
47567-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
16467
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
100000086598
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1711
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
m2040
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | Merck Index | ||
|
SUB20033
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
29952
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
94ZLA3W45F
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
317
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
7274
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
206269
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
6322
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1426
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
C62008
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
32682
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
SUB05560MIG
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
124
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
D001120
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
DB00125
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
ARGININE
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
94ZLA3W45F
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
CHEMBL1485
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1042500
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1091
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | RxNorm | ||
|
29016
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
74-79-3
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
1429
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
DTXSID6041056
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
200-811-1
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
32696
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY | |||
|
290
Created by
admin on Fri Dec 15 15:02:28 GMT 2023 , Edited by admin on Fri Dec 15 15:02:28 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SOLVATE->ANHYDROUS | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SUBSTRATE -> TARGET |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT |
ASSAY (HPLC)
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
PLASMA
|
||
|
METABOLITE -> PARENT |
PLASMA
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (TLC)
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |